Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: Comparison of PEG-Hirudin and unfractionated heparin

Thrombosis and Haemostasis

Volumn 76, Issue 1, 1996, Pages 105-110

  Rübsamen, Klaus ^a   Hornberger, Wilfried ^a  

^a Knoll AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; HEPARIN; HIRUDIN DERIVATIVE; LU 87981; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD CLOT LYSIS; CAROTID ARTERY FLOW; CAROTID ARTERY THROMBOSIS; CONTROLLED STUDY; DOG; DRUG EFFICACY; FEMALE; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECURRENT DISEASE; REPERFUSION; THROMBOCYTE AGGREGATION;

EID: 0030054431     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650531     Document Type: Article

References (43)

1. White HD, Norris RM, Browns MA, Takayama M, Maslowski A, Bass NM, Ormiston JA, Whitlock T. Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med 1987; 317: 850-5.
2. Sobel BE. Thrombolysis in the treatment of acute myocardial infarction. In: Fuster V, Verstraete M, eds. Thrombosis in cardiovascular disorders. Philadelphia: WB Saunders, 1992: 289-326.
3. Hoffmann JJML, Janssen WCM. Interactions between thrombolytic agents and platelets: Effects of plasmin on glycoproteins Ib and IIb/IIIa. Thromb Res 1992; 67: 711-9.
4. Rapold HJ, de Bono D, Arnold AER, Arnout J, De Cock F, Collen D, Verstraete M. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. Circulation 1992; 85: 928-34.
5. Szezeklik A, Dropinski J, Radwan J, Krzanowski M. Persistent generation of thrombin after acute myocardial infarction. Arterioscl Thromb 1992; 12: 548-53.
6. Mirshahi M, Soria J, Soria C, Faivre R, Lu H, Courtney M, Roitsch C, Tripier D, Caen JP. Evaluation of the inhibition by heparin and hirudin of coagulation activation during rt-PA-induced thrombolysis. Blood 1989; 74: 1025-30.
7. Gold HK, Yasuda T, Jang I-K, Guerrero JL, Fallon JT, Leinbach RC, Collen D. Animal models for arterial thrombolysis and prevention of reocclusion. Erythrocyte-rich versus platelet-rich thrombus. Circulation 1991; 83 (Suppl IV): IV-26-IV-40.
8. Yasuda T, Gold HK, Yaoita H, Leinbach RC, Guerrero JL, Jang I-K, Holt R, Fallon JT, Collen D. Comparative effects of aspirin, a synthetic thrombin inhibitor and a monoclonal antiplatelet glycoprotein IIb/IIIa antibody on coronary artery reperfusion, reocclusion and bleeding with recombinant tissue-type plasminogen activator in a canine preparation. J Am Coll Cardiol 1990; 16: 714-22.
9. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991; 83: 1048-56.
10. 2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 1992; 86: 1993-9.
11. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991; 77: 1006-12.
12. Heras M, Chesebro JH, Webster MWI, Mruk JS, Grill DE, Penny WJ, Bowie EJW, Badimon L, Fuster V. Hirudin, heparin, and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990; 82: 1476-84.
13. Buchwald AB, Sandrock D, Unterberg C, Ebbecke M, Nebendahl K, Lüders S, Munz D, Wiegand V. Platelet and fibrin deposition on coronary stents in minipigs: Effect of hirudin versus heparin. J Am Coll Cardiol 1993; 21: 249-54.
14. Schumacher WA, Heran CH, Steinbacher TE, Megill JR, Bird JE, Giancarli MR, Durham SK. Thrombin inhibition compared with other antithrombotic drugs in rats. Thromb Res 1992; 68: 157-66.
15. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992; 85: 805-15
16. Klement P, Borm A, Hirsh J, Maraganore J, Wilson G, Weitz J. The effect of thrombin inhibitors on tissue plasminogen activator induced thrombolysis in a rat model. Thromb Haemost 1992; 68: 64-8.
17. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-91.
18. Kaiser B, Hauptmann J. Pharmacology of synthetic thrombin inhibitors of the tripeptide type. Cardiovasc Drug Rev 1992; 10: 71-87.
19. Markwardt F, Richter M, Walsmann P, Riesener G, Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behaviour. Biomed Biochim Acta 1990; 49: 1103-8.
20. Rübsamen K, Hornberger W, Laux V, Schwarz M, Schweden J. Antithrombotic efficacy of the polyethyleneglycol-coupled hirudin mutein LU 57291 in experimentally induced venous and arterial thrombosis. Thromb Haemost 1993; 69: 2717 (Abstr.).
21. Kordenat RK, Kezdi P, Stanley EL. A new catheter technique for producing experimental coronary thrombosis and selective coronary visualization. Amer Heart J 1972; 83: 360-4.
22. Folts J. An in vivo model of experimental arterial stenosis, intimal damage, and periodic thrombosis. Circulation 1991; 83 (Suppl IV): IV-3-IV-14.
23. Brassard JA, Meyers KM. Evaluation of the buccal bleeding time and platelet glass bead retention as assays of hemostasis in the dog: The effects of acetylsalicylic acid, warfarin and von Willebrand factor deficiency. Thromb Haemost 1991; 65: 191-5.
24. Spannagl M, Bichler J, Birg A, Lill H, Schramm W. Development of a chromogenic substrate assay for the determination of hirudin in plasma. Blood Coagulation Fibrinolysis 1991; 2: 121-7.
25. Ohman EM, Califf RM, Topol EJ, Candela R, Abbottsmith C, Ellis S, Sigmon KN, Kereakes D, George B, Stack R. TAMI study group: Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990; 82: 781-91.
26. Rigel DF, Olson RW, Lappe RW. Comparison of hirudin and heparin as adjuncts to streptokinase thrombolysis in a canine model of coronary thrombosis. Circulation Res 1993; 72: 1091-102.
27. Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition. Cardiovasc Res 1994; 28: 78-85.
28. Jang IK, Gold HK, Leinbach RC, Fallen JT, Collen D. In vivo thrombin inhibition enhances and sustains arterial recanalization with recombinant tissue-type plasminogen activator. Circulation Res 1990; 67: 1552-61.
29. Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: A comparison with heparin in a canine model of coronary artery thrombosis. J Cardiovasc Pharmacol 1993; 21: 587-94.
30. Yao SK, McNatt J, Anderson HV, Eidt J, Cui K, Golino P, Glas-Greenwalt P, Maraganore J, Buja LM, Willerson JT. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion. Am J Physiol 1992; 262: H374-H379.
31. Voytik S, Badylak SF, Burke S, Klabunde RE, Henkin J, Simmons A. The protective effect of heparin in a dog model of rethrombosis following pharmacologic thrombolysis. Thromb Haemost 1990; 64: 438-44.
32. Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, Loscalzo J. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circulation Res 1992; 70: 829-34.
33. Théroux P, Pérez-Villa F, Waters D, Lespérance J, Shabani F, Bonan R. Randomized double-blind comparison of two doses of hirulog with heparin as adjunctive therapy to streptokinase to promote early patency of the infarct-related artery in acute myocardial infarction. Circulation 1995; 91: 2132-9.
34. Cannon CP, McCabe CH, Henry TD, Schweiger MJ, Gibson RS, Mueller HS. A pilot study of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator factor and aspirin for acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 5 trial. J Am Coll Cardiol 1994; 23: 993-1003.
35. Rote WE, Mu DX, Bates ER, Nedelman MA, Lucchesi BR. Prevention of rethrombosis after coronary thrombolysis in a chronic canine model. II. Adjunctive therapy with r-hirudin. J Cardiovasc Pharmacol 1994; 23: 203-11.
36. Gold HK, Torres FW, Garabedian HD, Werner W, Jang IK, Khan A, Hagstrom JN, Yasuda T, Leinbach RC, Newell JB, Bovill EG, Stump DC, Collen D. Evidence for a rebound phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris. JACC 1993; 21: 1039-47.
37. Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis. Circulation 1994; 89: 1802-9.
38. Prager NA, Torr-Brown SR, Sobel BE, Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. JACC 1993; 22: 296-301.
39. Antmann EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction. Safety report from the thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994; 90: 1624-30.
40. The global use of strategies to open occluded arteries (GUSTO) IIa investigators, Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
41. Neuhaus K-L, Essen Rv, Tebbe U, Jessel A, Heinrichs H, Mäurer W, Döring W, Harmjanz D, Kötter V, Kalhammer E, Simon H, Horacek T. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). Circulation 1994; 90: 1638-42.
42. Rübsamen K, Hornberger W, Ruf A, Bode C. The ecarin clotting time, a rapid and simple coagulation assay for monitoring hirudin and PEG-Hirudin in blood. Ann Hematol 1996; 72: A56.
43. Esslinger H-U, Dübbers K, Müller-Peltzer H. First data on safety and anticoagulant activity after single i.v. and s.c, PEG-hirudin-administration in healthy volunteers. Thromb Haemost 1995; 73: 2109.